NCT02566044View on ClinicalTrials.gov

Safety, Pharmacokinetics and Pharmacodynamics Study of Inhaled QBW276 in Patients With Cystic Fibrosis

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

September 27, 2017

Primary Completion Date

April 24, 2018

Study Completion Date

April 24, 2018

Conditions
Pulmonary Cystic Fibrosis
Interventions
OTHER

Placebo

Placebo

DRUG

QBW276

0.3 mg and 1.5 mg strengths

Trial Locations (4)

10032

Novartis Investigative Site, New York

45147

Novartis Investigative Site, Essen

50924

Novartis Investigative Site, Cologne

75390-9034

Novartis Investigative Site, Dallas

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY